Theranos CEO unveils 'miniLab' at Philadelphia conference

Theranos CEO unveils 'miniLab' at Philadelphia conference

Embattled Theranos founder and CEO Elizabeth Holmes was in Philadelphia Monday evening to speak about her company’s future, and very little about its controversial past, to a large and skeptical crowd at the American Association for Clinical Chemistry.

Holmes’ presentation focused on the company’s new miniLab product — a laboratory in a box that can perform cell counts and DNA tests — that Theranos has under development to provide a variety of diagnostic tests from only a few drops of blood. The product, which is about the size of a bread machine, has not yet been submitted to the Food and Drug Administration for approval.

She presented study data demonstrating how the miniLab's performance in blood tests matched or exceeded the performance of existing devised used to detect cholesterol levels, herpes and the Zika virus.

Theranos unveils new product, little data on existing tech

Theranos, based in Palo Alto, California, said it intends to submit the miniLab study results, and its interpretation of those results, for peer review.

The miniLab, Holmes said, supports the mission she had when starting the company in 2003 after dropping out of Stanford University. That mission is to make diagnostic tests that are less expensive and effective, and require just a small finger prick to get a blood sample.

“This is an inflection point for our company and a new chapter as we introduce our technologies to the world,” Homes said. “We will work as hard as it takes to realize our vision.”

More than 2,000 people attended the session where Holmes spoke, hundreds of whom started lining up for a seat an hour before her presentation.

Their skepticism was apparent when applause broke out after one of the first statements in a panel discussion after the presentation. Dr. Stephen Master, an associate professor of pathology and clinical medicine at Weill Cornell Medical College, questioned Holmes on earlier claims that the company had technology that could run 70-plus tests on a single drop of blood.

إبراهيم زكاغ

مدون وأحب القراءة وكل جديد التكنولوجيا والإنترنت . إنشاء فولفولي جاء من الرغبة في مشاركة تجربتي المتواضعة ولأكون مساهما ولو بالقليل في محتوى الإنترنت.

هنا كود أدسنس